Dr. Daniel Wallerstorfer
BUILDING BIOTECH COMPANIES
After university, Daniel founded the Austrian startup Novogenia in 2009 with the help of private investors. The company became profitable in 2013 and continues its profitable growth in the following years.
During the COVID Pandemic, Novogenia quickly became the leading laboratory for SARS-COV-2 testing in Austria, processing up to 275 000 samples per day. At the peak of the pandemic, Novogenia and its associated companies rapidly grew to 1500 employees, demonstrating its ability rapidly scale its analysis and production capabilities in short periods of time.
Besides managerial duties of a CEO, Daniel focuses most of his time on research, development and innovation. Under his direction, Novogenia developed new innovative genetic testing products, personalized supplement and cosmetics technologies and AI systems for genome interpretation.
In 2020, the mother company of Novogenia, DARWIN AG was listed on the Munich stock exchange and began to grow its coverage of the biotech field through investments and acquisitions.